CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether a new cell therapy called STEAP1 CAR T, given together with the hormone drug enzalutamide, is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC). The therapy uses a patient's own immune cells, modified in the lab to be…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control Recruiting nowThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Testosterone therapy shows promise for Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment involves raising and lowering testosterone levels in a controlled way to try to slow cancer growth. Th…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to halt tough prostate cancer
Disease control Recruiting nowThis study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Gene-Guided therapy could revolutionize prostate cancer care
Disease control Recruiting nowThis study tests whether analyzing a patient's tumor DNA and RNA can help doctors select the most effective treatment for advanced prostate cancer that no longer responds to hormone therapy. About 474 participants will receive one of several drugs based on their genetic profile. …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough prostate cancer? drug combo enters early trial
Disease control Recruiting nowThis early-phase trial is testing whether adding ruxolitinib to the standard drug enzalutamide can help men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The study will enroll 20 participants to find the safest dose and check for early s…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo aims to supercharge prostate cancer radiation
Disease control Recruiting nowThis study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Second dose of targeted radiation shows promise for tough prostate cancer
Disease control Recruiting nowThis study tests whether giving a second round of a radioactive drug called 177Lu-PSMA-617 can help men with advanced prostate cancer that no longer responds to hormone therapy. The drug targets and delivers radiation directly to cancer cells. Participants must have already had a…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo aims to make resistant prostate cancer vulnerable to radiation
Disease control Recruiting nowThis phase 2 trial tests whether adding vorinostat to the radioactive drug 177Lu-PSMA-617 can help men with PSMA-low metastatic castration-resistant prostate cancer. The goal is to increase PSMA levels on cancer cells so the radiation therapy works better. About 15 participants w…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Double chemo attack may stall tough prostate cancer
Disease control Recruiting nowThis phase III trial tests whether adding carboplatin to the standard chemo drug cabazitaxel helps men with metastatic castrate-resistant prostate cancer live longer without their cancer worsening. About 528 men will be randomly assigned to get cabazitaxel alone or cabazitaxel pl…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could High-Dose testosterone boost chemo against Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis phase 2 trial tests whether giving high levels of testosterone alongside chemotherapy (carboplatin or etoposide) or a targeted radioactive drug (LuPSMA) can shrink tumors in men with advanced prostate cancer that has stopped responding to hormone therapy. The study will enro…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment for men with a tough-to-treat form of prostate cancer that has spread and no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells t…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could fewer doses of this prostate cancer drug be just as good?
Disease control Recruiting nowThis phase II trial is testing whether giving 5 cycles of the radioactive drug Lu-177 PSMA-617 works as well as the standard 6 cycles for men with metastatic castration-resistant prostate cancer. The goal is to see if a shorter treatment course can control the cancer just as effe…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 26, 2026 15:59 UTC
-
Freezing and zapping: new combo therapy aims to ease bone cancer pain
Symptom relief Recruiting nowThis study tests whether adding cryoablation (a procedure that freezes and kills cancer cells) to standard radiation therapy provides better pain relief for people whose cancer has spread to their bones. About 40 participants with various cancers will be split into two groups: on…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Biopsies reveal secrets of therapy resistance in advanced prostate cancer
Knowledge-focused Recruiting nowThis study looks at why some prostate cancers become resistant to a targeted radiation treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors in 30 patients before and after therapy. The goal is to find genetic changes that cause resistance…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can DNA glitches predict prostate cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer cells make the drug radium-223 work better or worse. The goal is to help doctors choose the best treatment for each patient in …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC